Skip to main content
Log in

Ocrelizumab and alemtuzumab cost effective in RRMS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. 2017 US dollars

Reference

  • Zimmermann M, et al. Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis. CNS Drugs : 23 Aug 2018. Available from: URL: http://doi.org/10.1007/s40263-018-0566-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ocrelizumab and alemtuzumab cost effective in RRMS. PharmacoEcon Outcomes News 811, 22 (2018). https://doi.org/10.1007/s40274-018-5251-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5251-1

Navigation